Emily Campbell, MD
Internal Medicine · Columbia, SCNPI 1598392748
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $852, more than ten times the $25 reported in 2023.
Across 38 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$179
- AbbVie$157
- Novartis$109
- GSK$101
- UCB, Inc.$97
- Mallinckrodt Hospital Products Inc.$78
- plus $204 from 5 others
What the payments were for
- Food & beverage$924100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $179 |
| AbbVie | 6 | $157 |
| Novartis | 4 | $109 |
| GSK | 4 | $101 |
| UCB, Inc. | 4 | $97 |
| Mallinckrodt Hospital Products Inc. | 3 | $78 |
| AstraZeneca | 3 | $68 |
| Johnson & Johnson | 2 | $52 |
| Fresenius Kabi USA, LLC | 2 | $41 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Organon | 1 | $15 |
How this compares
$924 in reported general payments places this provider in the 65th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 18 | $133,991 |
| Actemra ActpenTocilizumab | 15 | $59,725 |
| MethotrexateMethotrexate Sodium | 75 | $2,126 |
| Hydroxychloroquine Sulfate | 26 | $853 |
| Methylprednisolone | 16 | $752 |
| Prednisone | 91 | $719 |
| Alendronate Sodium | 26 | $119 |
| Celecoxib | 13 | $108 |
| Naproxen | 11 | $73 |
| Sulfasalazine | 13 | $65 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Columbia
- Meer FakhryColumbia$22K
- Laura LabooneColumbia$16K
- Charles ButlerColumbia$15K
- Adelero AdebajoColumbia$12K
- Robert CollinsColumbia$11K
- Albert HumphreyColumbia$10K
- Elizabeth LebelColumbia$10K
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.